These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33125674)

  • 1. Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study.
    Zheng S; Shao F; Ding Y; Fu Z; Fu Q; Ding S; Xie L; Chen J; Zhou S; Zhang H; Zhou H; Chen Y; Sun C; Zhu J; Zheng X; Yang T
    Clin Drug Investig; 2020 Dec; 40(12):1155-1166. PubMed ID: 33125674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
    Morrow LA; Leonsson-Zachrisson M; Ericsson H; Wollbratt M; Knutsson M; Hompesch M; Norjavaara E
    Diabetes Obes Metab; 2012 Dec; 14(12):1114-22. PubMed ID: 22775976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the Influence of a High-Fat Meal on the Pharmacokinetics of Oral Globalagliatin, A Glucokinase Activator, in Healthy Chinese Volunteers.
    Xu M; Wang Y; Wang X; Pu Z; Liu Y; Jiang C; Shen X; Sun H; Xie H
    Drugs R D; 2024 Mar; 24(1):41-50. PubMed ID: 37985605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.
    Xu H; Sheng L; Chen W; Yuan F; Yang M; Li H; Li X; Choi J; Zhao G; Hu T; Li Y; Zhang Y; Chen L
    Drug Des Devel Ther; 2016; 10():1619-26. PubMed ID: 27274195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
    Xie P; Abildlund MT; Bækdal TA; He X; Lyauk YK; Patted URH; Ning Z; Shi A
    Diabetes Obes Metab; 2024 Aug; 26(8):3068-3077. PubMed ID: 38808476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
    Ericsson H; Röshammar D; Wollbratt M; Heijer M; Persson M; Ueda S; Leonsson-Zachrisson M; Norjavaara E
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):765-77. PubMed ID: 22943931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
    Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
    Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
    Zhi J; Zhai S
    J Clin Pharmacol; 2016 Feb; 56(2):231-8. PubMed ID: 26183686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
    Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
    Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
    Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.
    Katz L; Manamley N; Snyder WJ; Dodds M; Agafonova N; Sierra-Johnson J; Cruz M; Kaur P; Mudaliar S; Raskin P; Kewalramani R; Pellacani A
    Diabetes Obes Metab; 2016 Feb; 18(2):191-5. PubMed ID: 26434934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
    Kadokura T; Akiyama N; Kashiwagi A; Utsuno A; Kazuta K; Yoshida S; Nagase I; Smulders R; Kageyama S
    Diabetes Res Clin Pract; 2014 Oct; 106(1):50-6. PubMed ID: 25149596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
    Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
    Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
    Denney WS; Denham DS; Riggs MR; Amin NB
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
    Zhu XX; Zhu DL; Li XY; Li YL; Jin XW; Hu TX; Zhao Y; Li YG; Zhao GY; Ren S; Zhang Y; Ding YH; Chen L
    Diabetes Obes Metab; 2018 Sep; 20(9):2113-2120. PubMed ID: 29707866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.